Cell and gene therapies
New medicine requires new math
How will Medicaid pay for cell and gene therapies?
Read more CGT insights
Understanding barriers to access for sickle cell disease therapies
Beyond FDA approval: 5 factors in clinical trial design that influence health insurance coverage decisions
We detail factors in Phase-3 clinical trial design that influence health insurance coverage decisions.
CMS Cell and Gene Therapy Access Model
A look at the model’s benefits, limitations, and considerations for expansion.
Exploring the provider landscape in sickle cell disease through a gene therapy lens
What the CMS model will mean for patient access to breakthrough, high-cost treatment for sickle cell disease.
CGTs: Informing the uncertainties using research and retrospective claims analysis
Leveraging clinical research, market monitoring, and claims analysis to estimate cost exposure.
Complexities in forecasting eligible cases and associated costs of cell and gene therapy
Exploring the CGT pipeline, approvals, treatment rate, and more.
The uncertainties and benefits of gene and cell therapies: A payer's dilemma
Gene therapies, CAR T-cell therapies, and other innovative (and potentially curative) therapies are beginning to enter the market, and are making waves with their record-setting prices.
The future is now: Are payers ready for gene therapies?
Gene therapies for rare diseases may offer a life-changing treatment option for some patients, but can payers keep up with the cost?
Related Milliman products
Milliman DNA Gene and Cell Therapy Forecasting
Milliman Specialty Pharmacy Insights
